Baseline characteristics of patients receiving outpatient CAR T-cell therapy
| Baseline characteristics . | Patients with outpatient cell infusion (n = 58) . | All patients intended for outpatient administration (n = 64) . |
|---|---|---|
| Median age (range), y | 62 (21-82) | 62 (21-82) |
| Female | 47% (27) | 44% (28) |
| Race | ||
| Caucasian | 86.2% (50) | 87.6% (56) |
| African American | 5.2% (3) | 5% (3) |
| Hispanic | 3.4% (2) | 3.1% (2) |
| Asian | 3.4% (2) | 3.1% (2) |
| Other | 1.7% (1) | 1.6% (1) |
| Histology | ||
| Aggressive B-cell lymphoma | 39.7% (23) | 44% (28) |
| MCL | 1.7% (1) | 1.5% (1) |
| Myeloma | 56.9% (33) | 53% (34) |
| ALL | 1.7% (1) | 1.5% (1) |
| Median prior lines of therapy (range) | 4 (1-12) | 3 (1-12) |
| Previous auto-HCT | ||
| Aggressive B-cell lymphoma | 35% (8/23) | 36% (10/28) |
| MM | 91% (30/33) | 91% (31/34) |
| Previous allo-HCT | ||
| Aggressive B-cell lymphoma | 4.3% (1/23) | 3.6% (1/28) |
| MM | 27.3% (9/33) | 29.4% (10/34) |
| Bridging therapy | ||
| Aggressive B-cell lymphoma | 39% (9/23) | 43% (12/28) |
| MM | 33% (11/33) | 35% (12/34) |
| Median LDH before lymphodepletion | 205 (112-1228) | 205 (112-1228) |
| Type of CAR | ||
| Axi-cel | 17 | 22 |
| Tisa-cel | 1 | 1 |
| Liso-cel | 5 | 5 |
| Brexu-cel | 2 | 2 |
| Cilta-cel | 21 | 24 |
| Ide-cel | 9 | 10 |
| Lymphodepletion | ||
| Flu-Cy | 50% (29/58) | 52% (33/64) |
| Bendamustine | 50% (29/58) | 48% (31/64) |
| Baseline characteristics . | Patients with outpatient cell infusion (n = 58) . | All patients intended for outpatient administration (n = 64) . |
|---|---|---|
| Median age (range), y | 62 (21-82) | 62 (21-82) |
| Female | 47% (27) | 44% (28) |
| Race | ||
| Caucasian | 86.2% (50) | 87.6% (56) |
| African American | 5.2% (3) | 5% (3) |
| Hispanic | 3.4% (2) | 3.1% (2) |
| Asian | 3.4% (2) | 3.1% (2) |
| Other | 1.7% (1) | 1.6% (1) |
| Histology | ||
| Aggressive B-cell lymphoma | 39.7% (23) | 44% (28) |
| MCL | 1.7% (1) | 1.5% (1) |
| Myeloma | 56.9% (33) | 53% (34) |
| ALL | 1.7% (1) | 1.5% (1) |
| Median prior lines of therapy (range) | 4 (1-12) | 3 (1-12) |
| Previous auto-HCT | ||
| Aggressive B-cell lymphoma | 35% (8/23) | 36% (10/28) |
| MM | 91% (30/33) | 91% (31/34) |
| Previous allo-HCT | ||
| Aggressive B-cell lymphoma | 4.3% (1/23) | 3.6% (1/28) |
| MM | 27.3% (9/33) | 29.4% (10/34) |
| Bridging therapy | ||
| Aggressive B-cell lymphoma | 39% (9/23) | 43% (12/28) |
| MM | 33% (11/33) | 35% (12/34) |
| Median LDH before lymphodepletion | 205 (112-1228) | 205 (112-1228) |
| Type of CAR | ||
| Axi-cel | 17 | 22 |
| Tisa-cel | 1 | 1 |
| Liso-cel | 5 | 5 |
| Brexu-cel | 2 | 2 |
| Cilta-cel | 21 | 24 |
| Ide-cel | 9 | 10 |
| Lymphodepletion | ||
| Flu-Cy | 50% (29/58) | 52% (33/64) |
| Bendamustine | 50% (29/58) | 48% (31/64) |
Allo-HCT, allogeneic hematopoietic cell transplant; auto-HCT, autologous hematopoietic cell transplant; Brexu-cel, brexucabtagene autoleucel; Ide-cel, idecabtagene vicleucel; LDH, lactate dehydrogenase; Liso-cel, lisocabtagene maraleucel; Tisa-cel, tisagenlecleucel.